Kornimate/medical-research-clean huggingface dataset:
diaphragmatic ultrasound to predict the therapeutic effect of high-flow nasal cannula oxygen therapy

Conditions: Hypoxic Respiratory Failure

Summary: follow-up was conducted for every patient requiring high-flow nasal cannula oxygen therapy in district 1 of the intensive care department of chenzhou no.1 people's hospital. patients who met the inclusion criteria but did not meet the exclusion criteria were included for observation. respiratory parameters, diaphragmatic activity, and variation rate of diaphragmatic thickness were recorded at the beginning of high-flow nasal cannula oxygen therapy, 1 hour after treatment, 3 hours after treatment, 6 hours after treatment, 9 hours after treatment, and 12 hours after treatment. throughout the procedure, a panel of experts assessed whether the patient needed endotracheal intubation; if yes, the study was terminated; if no, high-flow nasal cannula oxygen therapy was continued, and observation and evaluation were continued until the end point of the study (12 hours after treatment). if patients or their family members do not want to continue to participate in the study during the study, they will be considered as withdrawal. if patients suffer from sudden malignant arrhythmia or cardiac arrest during the study, resulting in death or transfer to other hospitals or other departments during the study, patients will be excluded. data from dropped and excluded patients were not included in the final statistical analysis. after the data of 269 patients were collected, the study was concluded, and the results and conclusions were derived by statistical analysis.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years old, less than 75 years old,bmi≥18.5kg/m2 2. mild to moderate type i respiratory failure (100mmhg\< pao2/fio2≤300mmhg) 3. mild ventilation dysfunction (ph≥7.3) 4. mild respiratory distress (respiratory rate \> 24 times/min) 5. high-flow nasal cannula oxygen therapy is required 6. the patient and immediate family members agree and sign a written informed consent. exclusion criteria: 1. patients with severe type ii respiratory failure, severe asthma and massive hemoptysis 2. moderate to severe consciousness disorder, gcs score ≤12 points 3. cardiogenic pulmonary edema and cardiogenic dyspnea caused by heart failure, heart valvular disease, myocarditis, etc 4. hemodynamic instability, sbp\< 90mmhg, or map\<65mmhg 5. bmi \< 18.5kg/m2 6. nasal bleeding, nasal space occupying lesions, etc., can not be high-flow nasal cannula oxygen therapy through the nose or nasal obstruction 7. patients with severe hypoxemia, severe ards and other conditions requiring immediate tracheal intubation 8. the patient or family member refuses to participate or does not agree to sign the written informed consent 9. the patient has participated in other research projects with interventions
malaysian covid-19 anosmia study (phase 1) - a nationwide multicentre cross-sectional study

Conditions: SARS-CoV Infection; COVID-19; Anosmia; Dysgeusia

Summary: the malaysian covid-19 anosmia study is a nationwide multicentre observational study to investigate the prevalence and characteristics of olfactory and gustatory/taste disturbances in covid-19 infection in malaysia, and to evaluate the predictive value of screening for these symptoms in covid-19 infection. this study consists of two phases: the first phase is a cross-sectional study and the second phase is a case-control study. the cross-sectional study is described here (the case-control study is described in a separate clinicaltrials.gov record).

the world is currently in the midst of the coronavirus 2019 (covid-19) pandemic that is caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (sars-cov-2). according to published cohort studies on covid-19 infected patients, the most prevalent symptoms consist of fever, dry cough, dyspnoea, sputum production, myalgia, arthralgia, headache, diarrhoea, and sore throat. recently, there have been concerns of significant viral transmission through asymptomatic, pre-symptomatic or even mildly symptomatic patients. there is increasing anecdotal evidence from patients and healthcare professionals highlighting isolated loss of sense of smell (anosmia) and taste disturbances (dysgeusia) as atypical symptoms of covid-19 infection in otherwise asymptomatic patients. in parallel, expert statements from the british association of otorhinolaryngology-head \& neck surgery (ent uk), british rhinological society, and the american association of otolaryngology-head \& neck surgery (aao-hns) have suggested that olfactory and taste disturbances could be a clinical feature of covid-19 infection. rapidly emerging evidence from europe, the united kingdom and the united states have found olfactory and taste disturbances to be highly prevalent in patients diagnosed with covid-19. in contrast, there is currently limited evidence from asia on the prevalence of these symptoms in covid-19 infection. the aim of this cross-sectional study is to study the prevalence and characteristics of olfactory and taste disturbance in patients with covid-19 infection in malaysia. covid-19 positive patients will be recruited from participating malaysian ministry of health-designated covid-19 treating hospitals across the country. participants will answer an online questionnaire to evaluate and characterise these symptoms.

Eligibility criteria:
inclusion criteria: 1. age at least 18 years old 2. laboratory confirmed covid-19 infection \[reverse transcription polymerase chain reaction (rt-pcr)\] 3. patients clinically able to answer the questionnaire exclusion criteria: 1. patients with olfactory or taste/gustatory disorders before the covid-19 epidemic 2. patients without a laboratory-confirmed covid-19 diagnosis 3. patients in intensive care unit at the time of study

Keywords: cross-sectional study prevalence otorhinolaryngology infectious diseases anosmia dysgeusia olfactory disorders taste disorders covid-19 sars-cov-2 coronavirus 2019
impact of an intensive monitoring strategy in symptomatic patients with suspected arrhythmia

Conditions: Suspected Arrhythmia

Summary: hypothesis: patients that were previously discharged from the emergency department with a subsequent non-diagnostic 30 day external patch monitor for suspected arrhythmia will benefit from early reveal linq™ insertable cardiac monitoring system placement. primary study objectives: to evaluate the outcome of an intensive monitoring strategy (patients with a negative 30 day seeq™ mobile cardiac telemetry (mct) system result are purposed over for a reveal linq™ insertable cardiac monitoring system) in patients with suspected but no previously documented arrhythmias that result in a clinically actionable event.

eligible patients will be enrolled after presentation to the emergency department of st. elizabeth healthcare with symptoms suggestive of cardiac arrhythmia and prior to leaving the emergency department. patients will be exited from the study and considered complete at the identification of a cardiac arrhythmia as defined in the protocol (endpoint), or 12 months from enrollment date, whichever occurs first. protocol defined endpoints 1. planned insertion of a permanent pacemaker, implantable cardiac defibrillator or chronic resynchronization device. 2. planned cardiac ablation procedure. 3. initiation of medical therapy for the purpose of treating dysrhythmia. 4. diagnosis of arrhythmia not requiring medical or invasive arrhythmia management.

Eligibility criteria:
inclusion criteria: * \>18 years of age * patient present to the ed with symptoms suggestive of cardiac arrhythmia * english is the patient's primary language * willing and able to provide consent for participation in the study * patient is willing and able to comply with the protocol including the required follow-up exclusion criteria: * refusal to participate * age \< 18 years of age * unable to provide consent * current implanted loop recorder, or loop recorder explanted within the past 12 months. * current implant of cardiac implantable electronic device, such as permanent pacemaker (ppm), implantable cardioverter defibrillator (icd), or cardiac resynchronization therapy (crt) device. * life expectancy \< 12 months * history of prior cardiac ablation or electrophysiology study for suspected arrhythmia * investigator decision related to serious comorbidities or identification of reversible cause * unable to comply with follow-up procedures * previous documented diagnosis of cardiac arrhythmia by holter monitor, event monitor, ecg. * currently taking antiarrhythmic medication for a previously documented cardiac arrhythmia * history of or suspected diagnosis of postural orthostatic tachycardia syndrome (pots) * patient has unusual thoracic anatomy that precludes proper seeq patch placement * patient is enrolled in another study that could confound the results of this study
the omega-spm-dose and omega-spm-pad: specialized pro-resolving mediators in patients with peripheral artery disease

Conditions: Peripheral Arterial Disease; Claudication; Claudication, Intermittent; Vascular Occlusion; Vascular Calcification; Vascular Diseases; Osteoarthritis

Summary: the purpose of this study is to understand the effects of fish oil supplement (containing parts of omega-3 fatty acids) on inflammation. the investigators are aiming to identify which dose of the fish oil supplement is the most effective. the name of the fish oil supplement is "spm emulsion."

the omega-spm-dose trial and the omega-spm-pad trial are two parts of a pilot study which aims to investigate the effect of a novel formulation of a nutritional supplement containing highly concentrated n-3 pufa metabolites (spm emulsion) on the metabolo-lipidomic profile of healthy volunteers and patients with peripheral arterial disease(pad). ten healthy volunteers and ten patients with pad will participate in part 1a, the "omega-spm-dose study". a follow-up, placebo controlled, prospective study on the best dosing modality determined in phase 1a will then take place in a pad and oa population (n=12), phase 1b - the "omega-spm-pad study". specific measurements will include targeted metabolo-lipidomic profiling, established markers of inflammation, and functional monocyte and macrophage assays. the proposed studies have the potential to provide important new insights on the role of nutritional interventions in pad.

Eligibility criteria:
inclusion criteria: healthy volunteers: -age 20-80 pad patients: * mild claudication to rest pain (rutherford 1-4) * resting or exercise abi \< 0.9 or tbi \< 0.6 * age 40 and more oa patients: -lower extremity (hip or knee) oa exclusion criteria: pad, oa patients and healthy volunteers: * plan to undergo surgical procedure or pvi for treatment of pad within one month * evidence of active infection * hypersensitivity or allergy to fish or seafood * already on n-3 pufa or equivalent * chronic liver disease, end-stage renal disease (ckd 5), or chronic inflammatory disorders * poorly controlled diabetes (hba1c \> 8%) * bmi \ 35 * recent other major surgery or illness within 30 days * use of immunosuppressive medications or steroids * history of organ transplantation * pregnancy, or plans to become pregnant, or lactating healthy volunteers: * hscrp \> 2mg/l * regular aspirin use * regular non-steroidal anti-inflammatory drug use

Keywords: peripheral arterial disease claudication pad vascular disease vascular occlusion vacular calcification intermittent claudication osteoarthritis
multimodal therapeutic approach in undernourished maintenance hemodialysis patients (americano)

Conditions: Chronic Kidney Failure

Summary: the aim of the study is to evaluate a 3 months integrated multimodal therapeutic approach including exercise training program with ergocycle during dialysis sessions, oral nutritional supplementation, omega 3 and androgen, on effort tolerance and quality of life of under-nourish maintenance hemodialysis chronic kidney disease (ckd) patient.

the aim of the study is to evaluate a 3 months integrated multimodal therapeutic approach including exercise training program with ergocycle during dialysis sessions, oral nutritional supplementation, omega 3 and androgen, on effort tolerance and quality of life of under-nourish maintenance hemodialysis chronic kidney disease (ckd) patient.

Eligibility criteria:
inclusion criteria: * hemodialysis patient since at least 6 month * patient aged 18 years or older * written consent to participate in the study * no acute infection or hospitalization * opinion of cardiologist saying there is no known evidence against the evaluation of the maximum exercise capacity * protein-energy wasting diagnosed if at least two of this characteristics are present * serum albumin \<3.8 g per 100 ml (bromcresol green) * serum prealbumin (transthyretin) \<30mg per 100 ml * reduce body mass (bmi \<23) * unintentional 10% weight loss over 6 months * lean body mass index \< 10th percentile exclusion criteria: * presence of comorbidity which compromising the survival within 6 month * unintentional low dei \<20 kcal kg_1 day_1 * hiv or hcv positive * history of hormone dependent cancer * suspected or confirmed prostate cancer or breast carcinoma * known hypersensitivity for testosterone * presence or history of hepatic tumor * inability to follow the rehabilitation program * inadequate dialysis dosage (\<12 hours / week or kt/v index\< 1,2) pregnant or planning pregnancy and lactating women during study period * adult patient protected by law * patient who don't sign his informed consent

Keywords: physical exercises oral nutritional supplementation multimodal hemodialysis protein-energy wasting
inspiratory muscle training and asthma

Conditions: Asthma

Summary: this is a pilot study which will assess the feasibility of a follow on main study. this study will examine the impact of inspiratory muscle training on quality of life, rescue drug medication usage, and other markers of asthma in adult asthmatics in the uk.


Eligibility criteria:
inclusion criteria: * asthma control questionnaire score of ≥ 1.5 * 10 mg or less of prednisolone (or equivalent) daily * aged 18 to 59 years inclusive * able to provide written informed consent exclusion criteria: * any significant heart or lung disease other than asthma including any previous history of pneumothorax * patients with a concomitant condition (including clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease) not controlled with treatment, making implementation of the protocol or interpretation of the study results difficult * women who are pregnant * forced expiratory volume in one second of less than 50% best or predicted * a history of smoking 20 cigarettes a day for 20 years or more (or an equivalent amount) * undertaken a structured program of inspiratory muscle training within the past three months * currently a participant in another interventional study

Keywords: asthma, inspiratory muscle training
uncovered self-expandable metal stent versus double layer plastic stent for malignant hilar stricture

Conditions: Bile Duct Obstruction; Klatskin's Tumor

Summary: the overall median survival of nonresectable malignant hilar obstruction in most series has been less than 6 months. most patients with malignant hilar obstruction present with advanced disease, making palliative endoscopic drainage the principal therapeutic option. however, the optimal endoscopic management strategy is contentious. almost all of the published data comparing plastic and metallic stents relate to distal tumors (those of the pancreas, common bile duct and ampulla). stent patency, complication rates, and cost-effectiveness have favored metallic stents when compared with plastic stents in patients with distal malignant obstruction expected to live at least 3 to 6 months. there are few comparative study as to whether self-expanding metallic or plastic stent, especially dls (double layer plastic stent) are preferable in the technical success, stent patency, and cost-effectiveness for palliating malignant hilar obstruction. the study was designed to compare the the technical success, stent patency, and cost-effectiveness of self-expandable metal stent and dls in patients with malignant hilar obstruction.


Eligibility criteria:
inclusion criteria: * patient over 18 years old * patient with malignant hilar obstruction exclusion criteria: * no written informed consent * patient with uncorrectable severe coagulopathy * indication for surgical operation * karnofsky score \< 60%

Keywords: malignant hilar stricture
a study to investigate effects of gsk561679 on brain activation during emotional processing in healthy volunteers

Conditions: Depressive Disorder and Anxiety Disorders

Summary: this study will be conducted in healthy volunteers to investigate the effect of single dose gsk561679 on the changes of brain activation, as it compares to an active comparator, lorazepam.


Eligibility criteria:
inclusion criteria: * healthy males * non-smokers * body weight 50 kg (110 lbs) or higher, and bmi within the range 19-29.9 kg/m2 * normal ecg. exclusion criteria: * any serious medical disorder or condition. * any history of an endocrine disorder. * any clinically significant laboratory abnormality. * history of psychiatric illness. * any history of suicidal attempts or behavior. * history or current diagnosis of acute narrow angle glaucoma. * left handed

Keywords: gsk561679, single, dose, lorazepam, fmri, bold, healthy volunteers
an optimal dose finding study of n-acetylcysteine in patients with myeloproliferative neoplasms

Conditions: Myeloproliferative Neoplasm; MPN; Essential Thrombocythemia; Polycythemia Vera; Myelofibrosis

Summary: this is a phase i/ii study evaluating the optimal dose of n-acetylcysteine (n-ac) in patients with myeloproliferative neoplasms (mpn).

this is a phase i/ii open-label clinical trial determining the optimal biological dose (obd) of n-acetylcysteine in subjects with myeloproliferative neoplasms. these are subjects who have a diagnosis of essential thrombocythemia (et), polycythemia vera (pv), or myelofibrosis (mf).

Eligibility criteria:
inclusion criteria: * ≥18 years of age * have a diagnosis of essential thrombocythemia (et), polycythemia vera (pv), or myelofibrosis (mf) according to the 2016 who criteria * has not taken interferon-alpha or a jak inhibitor (such as ruxolitinib or fedratinib) for treatment of mpn in the past 28 days before enrollment. * may continue on current mpn treatment, including aspirin, hydroxyurea, or anagrelide. therapeutic phlebotomies should continue per the patient's usual regimen. * has not taken n-acetylcysteine (n-ac) or preparations containing n-ac in the past 28 days before enrollment. * baseline mpn-tss score of ≥ 10 at the time of enrollment. * peripheral blast count \<10% during screening. * free of other active or metastatic malignancies other than localized skin cancer. * amenable to blood draws and symptom assessments. * agree to the use of contraceptives. female subjects of childbearing potential and their male partners, or male subjects who have female partners of childbearing potential, should both use an effective contraception method during the study and continue to use contraception for 60 days after the last dose of study drug. exclusion criteria: * eastern cooperative oncology group (ecog) questionnaire score of ≥3 * currently pregnant or planning on being pregnant within the study period. * currently breastfeeding. * known uncontrolled active viral or bacterial infection. * significant impairment of major organ function defined as 1. serum creatinine clearance less than 50 ml/min (calculated with cockroft-gault formula). 2. bilirubin more than 1.5 mg/dl except for gilbert's disease. alt or ast more than 2x upper normal limit or has radiologic evidence of liver cirrhosis. 3. platelets \< 100 × 10\^9/l 4. hgb \< 10 g/dl 5. anc \< 0.75 × 10\^9/l * known history of allergic reaction to n-ac.

Keywords: mpn myeloproliferative neoplasm essential thrombocytemia polycythemia vera myelofibrosis
myocardial dommages related to covid-19

Conditions: Covid19; Non Ischemic Myocardial Injury; Myocardial Infarction; Myocarditis; Troponin Elevation

Summary: myocardial injury, as assessed by elevation of cardiac troponins (tnc), is frequent among patients with covid-19. although rare autopsy cases reported covid-19 related myocardial inflammation, the origin of tnc elevation is unknown to date. several cardiac causes, such as myocarditis, non-ischemic myocardial injury (nimi), or myocardial infarction (mi) may lead to tnc kinetic. our work will test the hypothesis that during sars-cov2 infection, the elevation of cardiac biomarkers could be linked to the occurrence of myocarditis.


Eligibility criteria:
inclusion criteria: * covid-19 positive patient hospitalized \< 72 h after symptoms onset with troponin assessement. exclusion criteria: * patients hospitalized \> 72h after symptom onset
ape-study: ablation of barrett's mucosa vs. surveillance without ablation in patients cured from barrett's cancer combined with randomization of esomeprazole vs. placebo for symptomatic reflux control after successful barrett's ablation

Conditions: Barrett's Esophagus

Summary: this is a prospective, randomized, controlled, double-blinded, multi-center trial in a parallel-group design. aim of the study is the evaluation of tumor-free survival after ablation (by apc, argon plasma coagulation) of barrett's mucosa plus esomeprazole versus surveillance without ablation in patients cured from barrett's cancer combined with randomization of esomeprazole vs placebo for symptomatic reflux control after successful ablation of barrett's mucosa . there are two hypotheses: (1) consecutive thermal ablation of metaplastic, non-neoplastic long segments of barrett's esophagus (\>2cm)plus esomeprazole after successful endoscopic therapy of mucosal cancer by means of er will decrease the incidence of secondary cancer (local recurrence and metachronous cancer) by a minimum of 50% compared to acid suppression alone without ablation within a 5-years follow-up (primary endpoint). (2) after successful ablation of barrett's esophagus patients need ongoing acid suppression therapy for medical control of their underlying reflux disease (secondary aim of the study). duration of the study: patient recruitment period: 3 years. follow-up period: 5 years. total duration: 8 years. the study is already in the recruitment period.


Eligibility criteria:
inclusion criteria: * endoscopically and histologically complete remission of mucosal barrett's cancer (endoscopic resection with or without thermal ablation of resection margins) * initial length of barrett's segment before cancer therapy \> 3 cm (initially long-segment barrett's esophagus) * barrett's length after endoscopic therapy of barrett's cancer \> 2 cm * informed consent of the patient exclusion criteria: * attempted ablation therapy before the trial * treatment duration of early barrett's cancer \> 12 months * duration between achievement of complete remission and attempted inclusion into the study \> 24 months * the barrett's cancer treated has already been a secondary lesion of earlier barrett's cancer * inadequate healing of endoscopic resection (er) ulcers * no residual barrett's mucosa observed after pretreatment with er * no ppi compliance * relevant comorbidity (e.g., malignancy) * pregnancy * age below 18 years * patient not able to understand study characteristics * no written informed consent available * allergy against esomeprazole or intolerance of medication ingredients

Keywords: barrett's esophagus ablation esomeprazole barrett's cancer ablation of barrett's esophagus surveillance of barrett's esophagus after endoscopic resection of barrett's cancer recurrence of barrett's cancer